Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Biolife Science

Biolife Science
2012 FOUNDED
PUBLIC STATUS
1-10 EMPLOYEES
IMU STOCK SYMBOL
$0.02 SHARE PRICE (As of Thursday Closing)
Description

Imugene Ltd specializes is a clinical-stage immuno-oncology company. Its product includes HER-Vaxx, a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. The company is also developing B-cell peptide cancer vaccines and therapeutics. Its only operating segment being Research, Development, and Commercialisation of oncolytic immunotherapies.

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Drug Discovery
Stock Exchange
ASX
Primary Office
  • Level 11, 66 Eagle Street
  • Brisbane, Queensland 4000
  • Australia

+61 0402 000 000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Biolife Science’s full profile, request a free trial.

Biolife Science Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$59.1M $0.02 27.3M 3.61B

Biolife Science Financials Summary

In Thousands,
USD
TTM
31-Dec-2019
FY 2019
30-Jun-2019
FY 2018
30-Jun-2018
FY 2017
30-Jun-2017
Enterprise Value 67,616 23,507 51,918 21,746
EBITDA (5,807) (3,118) (1,914)
Net Income (5,560) (3,047) (1,889)
Total Assets 21,556 12,425 9,742
Total Debt 86 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Biolife Science Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Biolife Science‘s full profile, request access.

Request full access to PitchBook

Biolife Science Executive Team (1)

Name Title Board
Seat
Contact
Info
Paul Hopper Chief Operating Officer & Director